hydroxychloroquine has been researched along with Carcinoma, Non-Small Cell Lung in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, C | 1 |
| Maity, AP | 1 |
| Bauml, JM | 1 |
| Long, Q | 1 |
| Aleman, T | 1 |
| Ciunci, C | 1 |
| D'Avella, C | 1 |
| Volpe, M | 1 |
| Anderson, E | 1 |
| Jones, LM | 1 |
| Sun, L | 1 |
| Singh, AP | 1 |
| Marmarelis, ME | 1 |
| Cohen, RB | 1 |
| Langer, CJ | 1 |
| Amaravadi, R | 1 |
| Malhotra, J | 1 |
| Jabbour, S | 1 |
| Orlick, M | 1 |
| Riedlinger, G | 1 |
| Guo, Y | 1 |
| White, E | 1 |
| Aisner, J | 1 |
| Montrone, M | 1 |
| Catino, A | 1 |
| Palmieri, VO | 1 |
| Longo, V | 1 |
| Galetta, D | 1 |
| Li, Y | 1 |
| Cao, F | 1 |
| Li, M | 1 |
| Li, P | 1 |
| Yu, Y | 1 |
| Xiang, L | 1 |
| Xu, T | 1 |
| Lei, J | 1 |
| Tai, YY | 1 |
| Zhu, J | 1 |
| Yang, B | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Duo, L | 1 |
| Chen, P | 1 |
| Yu, X | 1 |
| Leung, LS | 1 |
| Neal, JW | 2 |
| Wakelee, HA | 1 |
| Sequist, LV | 2 |
| Marmor, MF | 1 |
| Ruan, Y | 1 |
| Hu, K | 1 |
| Chen, H | 1 |
| Zhang, WC | 1 |
| Chin, TM | 1 |
| Yang, H | 1 |
| Nga, ME | 1 |
| Lunny, DP | 1 |
| Lim, EK | 1 |
| Sun, LL | 1 |
| Pang, YH | 1 |
| Leow, YN | 1 |
| Malusay, SR | 1 |
| Lim, PX | 1 |
| Lee, JZ | 1 |
| Tan, BJ | 1 |
| Shyh-Chang, N | 1 |
| Lim, EH | 1 |
| Lim, WT | 1 |
| Tan, DS | 1 |
| Tan, EH | 1 |
| Tai, BC | 1 |
| Soo, RA | 1 |
| Tam, WL | 1 |
| Lim, B | 1 |
| Goldberg, SB | 1 |
| Supko, JG | 1 |
| Muzikansky, A | 1 |
| Digumarthy, S | 1 |
| Fidias, P | 1 |
| Temel, JS | 1 |
| Heist, RS | 1 |
| Shaw, AT | 1 |
| McCarthy, PO | 1 |
| Lynch, TJ | 1 |
| Sharma, S | 1 |
| Settleman, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced NSCLC[NCT01026844] | Phase 1 | 27 participants (Actual) | Interventional | 2007-07-31 | Terminated (stopped due to slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HCQ doses tested included 400mg, 600mg, 800mg, and 1000mg. Dose-limiting toxicities (DLTs) were defined as CTC of grade 2 or higher retinopathy or keratitis, or CTC of grade 3 or higher hematologic, skin, CNS, neuropathic, cardiac, respiratory, gastrointestinal, or renal AEs in the first cycle considered at least possibly related to HCQ. If a DLT was observed, an additional three patients were enrolled at that dose level. The maximum tolerated dose for HCQ in each arm would be defined as one dose level below that at which two or more of 6 patients experienced a DLT, or if no DLTs were observed, the highest tested dose. (NCT01026844)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Erlotinib Plus HCQ (Hydroxychloroquine) | 0 |
| HCQ (Hydroxychloroquine) | 0 |
PK parameter tested was dose normalized minimum steady state concentration (Cmin SS) of HCQ in micromolar per gram. Note this outcome was only analyzed for the first 21 patients enrolled, 13 on erlotinib/HCQ and 8 on HCQ arm. (NCT01026844)
Timeframe: 2 years
| Intervention | micromolar per gram (Mean) |
|---|---|
| Erlotinib Plus HCQ (Hydroxychloroquine) | 5.93 |
| HCQ (Hydroxychloroquine) | 9.40 |
Number of Response Evaluation Criteria in Solid Tumors (RECIST) responses divided by number of patients treated. Per RECIST version 1.0 complete response (CR) is defined as disappearance of all target lesions; Partial Response (PR) is defined as >=30% decrease in the sum of the longest diameter of target lesions. The objective tumor response rate is the CR + PR divided by the total number of patients (NCT01026844)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Erlotinib Plus HCQ (Hydroxychloroquine) | 5 |
| HCQ (Hydroxychloroquine) | 0 |
4 trials available for hydroxychloroquine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hydr | 2023 |
Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Ag | 2019 |
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Topics: Aged; Antineoplastic Agents; Antirheumatic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Com | 2015 |
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2012 |
4 other studies available for hydroxychloroquine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.
Topics: Aged; Anaplastic Lymphoma Kinase; Anti-HIV Agents; Betacoronavirus; Carbazoles; Carcinoma, Non-Small | 2020 |
Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages.
Topics: A549 Cells; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; | 2018 |
Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell | 2015 |
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 2016 |